GT201700056A - Uso de agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamento de la enfermedad del hígado graso no alcohólico. - Google Patents
Uso de agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamento de la enfermedad del hígado graso no alcohólico.Info
- Publication number
- GT201700056A GT201700056A GT201700056A GT201700056A GT201700056A GT 201700056 A GT201700056 A GT 201700056A GT 201700056 A GT201700056 A GT 201700056A GT 201700056 A GT201700056 A GT 201700056A GT 201700056 A GT201700056 A GT 201700056A
- Authority
- GT
- Guatemala
- Prior art keywords
- long
- fatty liver
- alcoholic fatty
- liver disease
- glucagon receptor
- Prior art date
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract 4
- 108010063919 Glucagon Receptors Proteins 0.000 title abstract 3
- 102100040890 Glucagon receptor Human genes 0.000 title abstract 3
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title abstract 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 3
- 102100040918 Pro-glucagon Human genes 0.000 title abstract 3
- 229940125542 dual agonist Drugs 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000051325 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA PARA LA PREVENCIÓN O TRATAMIENTO DE LA ENFERMEDAD DEL HÍGADO GRASO NO ALCOHÓLICO QUE INCLUYE UN AGONISTA DUAL DEL RECEPTOR DE GLP-1/GLUCAGÓN DE ACCIÓN PROLONGADA, Y UN MÉTODO PARA LA PREVENCIÓN O TRATAMIENTO DE LA ENFERMEDAD DEL HÍGADO GRASO NO ALCOHÓLICO QUE INCLUYE ADMINISTRAR LA COMPOSICIÓN. LA COMPOSICIÓN DE LA PRESENTE INVENCIÓN YA SEA NO TIENE EFECTO SECUNDARIO DE GANANCIA DE PESO O REDUCE EL EFECTO SECUNDARIO DE LOS AGENTES TERAPÉUTICOS CONVENCIONALES PARA LA ENFERMEDAD DEL HÍGADO GRASO NO ALCOHÓLICO, Y REDUCE LA CANTIDAD DE ADMINISTRACIONES DE UN AGONISTA DUAL DEL RECEPTOR DE GLP-1/GLUCAGÓN DE ACCIÓN PROLONGADA, MEJORANDO ASÍ LA COMODIDAD DEL PACIENTE. ADEMÁS, EL AGONISTA DUAL DEL RECEPTOR DE GLP-1/GLUCAGÓN DE ACCIÓN PROLONGADA DE LA PRESENTE INVENCIÓN MEJORA LA SOSTENIBILIDAD Y ESTABILIDAD IN VIVO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140122862 | 2014-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201700056A true GT201700056A (es) | 2019-08-09 |
Family
ID=55533503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201700056A GT201700056A (es) | 2014-09-16 | 2017-03-14 | Uso de agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamento de la enfermedad del hígado graso no alcohólico. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10233230B2 (es) |
| EP (1) | EP3197483A4 (es) |
| JP (2) | JP6832273B2 (es) |
| KR (3) | KR102541971B1 (es) |
| CN (1) | CN107106660B (es) |
| AR (1) | AR101896A1 (es) |
| AU (3) | AU2015318881A1 (es) |
| CA (1) | CA2960657A1 (es) |
| CL (1) | CL2017000638A1 (es) |
| CO (1) | CO2017002689A2 (es) |
| CR (1) | CR20170129A (es) |
| EA (1) | EA201790568A1 (es) |
| EC (1) | ECSP17022931A (es) |
| GT (1) | GT201700056A (es) |
| IL (2) | IL251060B (es) |
| MA (1) | MA40466A (es) |
| MX (2) | MX2017003438A (es) |
| MY (2) | MY178378A (es) |
| NI (1) | NI201700032A (es) |
| NZ (1) | NZ730799A (es) |
| PE (1) | PE20170778A1 (es) |
| PH (1) | PH12017500486A1 (es) |
| SG (1) | SG11201701841WA (es) |
| TW (2) | TWI802396B (es) |
| WO (1) | WO2016043533A1 (es) |
| ZA (2) | ZA201701847B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164680A (en) | 2011-06-17 | 2018-01-30 | Hanmi Science Co Ltd | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
| NZ731658A (en) | 2012-11-06 | 2020-05-29 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| TWI802396B (zh) * | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| TW201639878A (zh) | 2014-12-30 | 2016-11-16 | 韓美藥品股份有限公司 | 具有改善之安定性的升糖素衍生物 |
| AU2016287209B2 (en) | 2015-06-30 | 2023-03-02 | Hanmi Pharm. Co., Ltd. | Glucagon derivative and a composition comprising a long acting conjugate of the same |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| AU2016382393B2 (en) | 2015-12-31 | 2019-07-04 | Hanmi Pharm. Co., Ltd. | Triple glucagon/GLP-1/GIP receptor agonist |
| CN115181175A (zh) | 2016-04-22 | 2022-10-14 | 深圳市图微安创科技开发有限公司 | Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化 |
| AU2017289014B2 (en) | 2016-06-29 | 2019-12-05 | Hanmi Pharm. Co., Ltd. | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
| CA3052410A1 (en) | 2017-02-03 | 2018-08-09 | Hanmi Pharm. Co., Ltd. | Conjugate of bioactive material having enhanced sustainability and use thereof |
| WO2019085773A1 (zh) * | 2017-11-06 | 2019-05-09 | 中山大学 | 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗特发性肺间质纤维化 |
| WO2019085772A1 (zh) * | 2017-11-06 | 2019-05-09 | 深圳市图微安创科技开发有限公司 | 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化 |
| DK3735295T3 (da) * | 2018-01-03 | 2024-11-25 | Mederis Diabetes Llc | Forbedrede peptidfarmaceutika til behandling af nash og andre lidelser |
| WO2019171352A2 (en) * | 2018-03-08 | 2019-09-12 | Janssen Pharmaceutica Nv | Methods of treating severe non-diabetic obesity |
| JP7589049B2 (ja) | 2018-06-21 | 2024-11-25 | ノヴォ ノルディスク アー／エス | 肥満を治療するための新規化合物 |
| WO2020128967A2 (en) * | 2018-12-19 | 2020-06-25 | Janssen Pharmaceutica Nv | Methods of treating severe non-diabetic obesity |
| CN114853908B (zh) * | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| TN2021000076A1 (en) * | 2019-06-28 | 2023-01-05 | Hanmi Pharmaceutical Co Ltd | Therapeutic use, for liver disease, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof |
| WO2021010531A1 (ko) * | 2019-07-18 | 2021-01-21 | 한미약품 주식회사 | 단백질 결합체의 신규 제조 방법 |
| KR20210103265A (ko) * | 2020-02-13 | 2021-08-23 | 주식회사 제넥신 | 신규 비알코올성 지방간염 치료용 약학 조성물 |
| KR102349717B1 (ko) * | 2020-03-12 | 2022-01-11 | 주식회사 에스엘메타젠 | 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물 |
| US11135220B1 (en) | 2020-04-08 | 2021-10-05 | St Ip Holding Ag | Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione |
| WO2021221482A1 (ko) | 2020-04-29 | 2021-11-04 | 주식회사 원진바이오테크놀로지 | 신규한 단백질 결합체, 및 이의 비알콜성 지방간염, 비만 및 당뇨 질환의 예방 또는 치료 용도 |
| CN113292646B (zh) * | 2020-05-29 | 2022-05-13 | 东莞云璟生物技术有限公司 | Glp-1/胰高血糖素双重激动剂融合蛋白 |
| WO2022015039A1 (ko) * | 2020-07-14 | 2022-01-20 | (주)지아이이노베이션 | 글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도 |
| CN112472794A (zh) * | 2020-11-17 | 2021-03-12 | 深圳市图微安创科技开发有限公司 | 双靶点激动剂多肽治疗anit介导的pbc及其相关的肝纤维化 |
| WO2022139489A1 (ko) | 2020-12-22 | 2022-06-30 | (주)메디엔진 | 알코올성 및 비알코올성 지방간의 예방 또는 치료용 약학 조성물 |
| CN112625093B (zh) * | 2020-12-29 | 2022-12-23 | 清远市图微安创科技开发有限公司 | 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物 |
| WO2022178366A1 (en) * | 2021-02-21 | 2022-08-25 | Spitfire Pharma Llc | Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use |
| US20240239843A1 (en) | 2021-09-15 | 2024-07-18 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| CN116589536B (zh) * | 2023-05-18 | 2024-01-23 | 江苏师范大学 | 一类长效glp-1/gip受体双重激动剂及其应用 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| AU749815B2 (en) | 1998-03-06 | 2002-07-04 | Chugai Seiyaku Kabushiki Kaisha | Protein-free preparations |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| WO2005047336A1 (en) | 2003-11-13 | 2005-05-26 | Hanmi Pharmaceutical. Co. Ltd. | Protein complex using immunoglobulin fragment andmethod for the preparation thereof |
| US7217845B2 (en) | 2002-11-25 | 2007-05-15 | Sun Bio, Inc. | Bifunctional polyethylene glycol derivatives |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2005035761A1 (en) | 2003-10-16 | 2005-04-21 | Compugen Ltd. | Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin |
| US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| US20090238838A1 (en) | 2003-11-13 | 2009-09-24 | Hanmi Pharm. Ind. Co. Ltd. | Insulinotropic peptide conjugate using an immunoglobulin fc |
| KR101135244B1 (ko) | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
| KR20070094909A (ko) | 2004-12-02 | 2007-09-27 | 도만티스 리미티드 | 혈청 알부민 및 ｇｌｐ-1 또는 ｐｙｙ를 표적으로 삼는이중특이성 도메인을 갖는 항체 |
| SG159551A1 (en) | 2005-02-11 | 2010-03-30 | Amylin Pharmaceuticals Inc | Gip analog and hybrid polypeptides with selectable properties |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| GB0511986D0 (en) | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| PT1891105E (pt) | 2005-06-13 | 2012-06-27 | Imp Innovations Ltd | Análogos de oxintomodulina e seus efeitos sobre o comportamento da alimentação |
| EP1922336B1 (en) | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| US20090297496A1 (en) * | 2005-09-08 | 2009-12-03 | Childrens Hospital Medical Center | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases |
| EP2471811B1 (en) | 2006-02-22 | 2015-09-16 | Merck Sharp & Dohme Corp. | Oxyntomodulin derivatives |
| WO2007146038A2 (en) | 2006-06-07 | 2007-12-21 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| GB0624868D0 (en) | 2006-12-13 | 2007-01-24 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| JP6017754B2 (ja) | 2007-02-15 | 2016-11-02 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴン／ｇｌｐ−１受容体コアゴニスト |
| AU2008275180A1 (en) | 2007-07-10 | 2009-01-15 | Eli Lilly And Company | GLP-1-Fc fusion protein formulation |
| JP5345617B2 (ja) | 2007-07-27 | 2013-11-20 | バイエル・クロップサイエンス・アーゲー | 三元活性化合物組合せ |
| CA2699065A1 (en) | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| WO2009058734A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
| CA2713348C (en) | 2008-01-30 | 2018-10-09 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| CN103641907A (zh) | 2008-06-17 | 2014-03-19 | 印第安纳大学研究及科技有限公司 | 胰高血糖素/glp-1受体共激动剂 |
| KR20110039230A (ko) | 2008-06-17 | 2011-04-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체 |
| WO2010013012A2 (en) | 2008-08-01 | 2010-02-04 | Lund University Bioscience Ab | Novel polypeptides and uses thereof |
| WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| WO2010033220A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Modified therapeutics peptides, methods of their preparation and use |
| DK2370461T3 (da) | 2008-12-15 | 2013-12-16 | Zealand Pharma As | Glucagonanaloger |
| WO2010071807A1 (en) | 2008-12-19 | 2010-06-24 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| AU2010226392B9 (en) | 2009-03-20 | 2014-05-22 | Amgen Inc. | Selective and potent peptide inhibitors of Kv1.3 |
| RU2495881C2 (ru) | 2009-03-20 | 2013-10-20 | Ханми Холдингс Ко., Лтд. | Способ регулирования условий для сайт-специфического связывания полипептида и непептидильного полимера |
| CA2765026A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| EA022816B1 (ru) | 2009-07-13 | 2016-03-31 | Зилэнд Фарма А/С | Ацилированные аналоги глюкагона |
| WO2011056713A2 (en) | 2009-11-03 | 2011-05-12 | Amylin Pharmaceuticals, Inc. | Glp-1 receptor agonist compounds for obstructive sleep apnea |
| MX2012005912A (es) * | 2009-11-23 | 2012-10-05 | Amylin Pharmaceuticals Inc | Conjugado de polipeptido. |
| EP2509997B1 (en) | 2009-12-07 | 2017-08-30 | i2 Pharmaceuticals, Inc. | Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
| EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
| AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
| AR079345A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
| EP2552950A1 (en) | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
| EP2568993A4 (en) | 2010-05-13 | 2014-02-19 | Univ Indiana Res & Tech Corp | GLUCAGON SUPERFAMILY PEPTIDES WITH G-PROTEIN-COUPLED RECEPTOR ACTIVITY |
| WO2011163012A2 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| KR101337797B1 (ko) | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| CN101974077A (zh) | 2010-09-15 | 2011-02-16 | 南京瑞年天平医药科技有限公司 | 一种新颖的多肽化合物 |
| KR101767570B1 (ko) | 2010-10-26 | 2017-08-14 | 한미사이언스 주식회사 | 항 비만 펩타이드의 지속형 결합체 |
| KR101303388B1 (ko) | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
| CN102010473A (zh) | 2010-11-10 | 2011-04-13 | 曹鹏 | 重组胃泌酸调节素融合蛋白及其制备和应用 |
| AR083878A1 (es) * | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| US8975223B2 (en) * | 2010-12-22 | 2015-03-10 | Marcadia Biotech, Inc. | Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146 |
| EP2492749A1 (en) | 2011-02-28 | 2012-08-29 | Rohm and Haas Electronic Materials LLC | Photoresist compositions and methods of forming photolithographic patterns |
| KR101161526B1 (ko) | 2011-05-16 | 2012-07-02 | 숭실대학교산학협력단 | 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법 |
| UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| RU2612906C2 (ru) | 2011-06-10 | 2017-03-13 | Ханми Сайенс Ко., Лтд. | Новые производные оксинтомодулина и содержащая их фармацевтическая композиция для лечения ожирения |
| MY164680A (en) | 2011-06-17 | 2018-01-30 | Hanmi Science Co Ltd | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
| RU2014101697A (ru) | 2011-06-22 | 2015-07-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Коагонисты рецепторов глюкагона/glp-1 |
| EP2723359A4 (en) * | 2011-06-24 | 2015-03-11 | Amylin Pharmaceuticals Llc | METHOD FOR THE TREATMENT OF DIABETES WITH THE HELP OF DELAYED RELEASED FORMULATIONS FROM GLP-1 RECEPTOR AGONISTS |
| KR101665009B1 (ko) | 2012-03-09 | 2016-10-11 | 한미사이언스 주식회사 | 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물 |
| AU2013250711A1 (en) | 2012-04-19 | 2014-11-27 | Opko Biologics Ltd. | Long-acting oxyntomodulin variants and methods of producing same |
| TWI599575B (zh) | 2012-06-21 | 2017-09-21 | 印第安納大學科技研究公司 | 表現ｇｉｐ受體活性之胰高血糖素類似物 |
| KR101968344B1 (ko) * | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| KR101373563B1 (ko) | 2012-07-25 | 2014-03-12 | 전북대학교산학협력단 | Ｔｏｆ-ｍｒａ를 이용한 혈류특성 및 ｍｒ-신호강도구배(전단율) 유도방법 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| KR101993393B1 (ko) * | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| NZ731658A (en) * | 2012-11-06 | 2020-05-29 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| JP6137046B2 (ja) | 2014-05-09 | 2017-05-31 | 信越化学工業株式会社 | 単量体、高分子化合物、レジスト材料及びパターン形成方法 |
| TWI802396B (zh) * | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
-
2015
- 2015-09-14 TW TW111117002A patent/TWI802396B/zh active
- 2015-09-14 TW TW104130263A patent/TWI772252B/zh active
- 2015-09-16 EP EP15841809.5A patent/EP3197483A4/en not_active Withdrawn
- 2015-09-16 SG SG11201701841WA patent/SG11201701841WA/en unknown
- 2015-09-16 CR CR20170129A patent/CR20170129A/es unknown
- 2015-09-16 US US15/511,405 patent/US10233230B2/en active Active
- 2015-09-16 CA CA2960657A patent/CA2960657A1/en active Pending
- 2015-09-16 AU AU2015318881A patent/AU2015318881A1/en not_active Abandoned
- 2015-09-16 MY MYPI2017700846A patent/MY178378A/en unknown
- 2015-09-16 MX MX2017003438A patent/MX2017003438A/es unknown
- 2015-09-16 MA MA040466A patent/MA40466A/fr unknown
- 2015-09-16 MY MYPI2020003068A patent/MY195618A/en unknown
- 2015-09-16 NZ NZ730799A patent/NZ730799A/en unknown
- 2015-09-16 CN CN201580061525.9A patent/CN107106660B/zh active Active
- 2015-09-16 JP JP2017514869A patent/JP6832273B2/ja active Active
- 2015-09-16 WO PCT/KR2015/009753 patent/WO2016043533A1/en active Application Filing
- 2015-09-16 PE PE2017000462A patent/PE20170778A1/es unknown
- 2015-09-16 KR KR1020150131004A patent/KR102541971B1/ko active Active
- 2015-09-16 AR ARP150102970A patent/AR101896A1/es not_active Application Discontinuation
- 2015-09-16 EA EA201790568A patent/EA201790568A1/ru unknown
-
2017
- 2017-03-09 IL IL251060A patent/IL251060B/en active IP Right Grant
- 2017-03-14 PH PH12017500486A patent/PH12017500486A1/en unknown
- 2017-03-14 GT GT201700056A patent/GT201700056A/es unknown
- 2017-03-15 CL CL2017000638A patent/CL2017000638A1/es unknown
- 2017-03-15 NI NI201700032A patent/NI201700032A/es unknown
- 2017-03-15 MX MX2022007012A patent/MX2022007012A/es unknown
- 2017-03-15 ZA ZA2017/01847A patent/ZA201701847B/en unknown
- 2017-03-22 CO CONC2017/0002689A patent/CO2017002689A2/es unknown
- 2017-04-13 EC ECIEPI201722931A patent/ECSP17022931A/es unknown
-
2019
- 2019-02-05 US US16/267,880 patent/US10435459B2/en active Active
- 2019-06-13 ZA ZA2019/03822A patent/ZA201903822B/en unknown
- 2019-08-14 IL IL268702A patent/IL268702B/en active IP Right Grant
-
2020
- 2020-09-24 JP JP2020159894A patent/JP2021035942A/ja not_active Withdrawn
-
2021
- 2021-05-14 AU AU2021203106A patent/AU2021203106B2/en active Active
-
2023
- 2023-06-05 KR KR1020230072287A patent/KR102762409B1/ko active Active
-
2024
- 2024-10-25 AU AU2024227659A patent/AU2024227659A1/en active Pending
-
2025
- 2025-01-24 KR KR1020250011523A patent/KR20250024003A/ko active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201700056A (es) | Uso de agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamento de la enfermedad del hígado graso no alcohólico. | |
| CL2019003091A1 (es) | Terapia de combinación. | |
| CL2018001007A1 (es) | Composiciones farmacéuticas para terapias combinadas (sol. divisional de n° 201702538). | |
| MX2024001204A (es) | Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con derivados de aceite de pescado para usarse en tratar enfermedades del higado graso. | |
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| MX390954B (es) | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| MX2016015669A (es) | Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon. | |
| MX384234B (es) | Uso de pridopidina para el tratamiento de enfermedad de huntington. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| MX2018001723A (es) | Conjugados farmaco-multiligando y usos de los mismos. | |
| ECSP15008695A (es) | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
| MX390627B (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| MX2018005715A (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| CL2017001843A1 (es) | Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2. | |
| CL2019003533A1 (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| CL2019000753A1 (es) | Composición farmacéutica que comprende antagonista de receptor mineralocorticoide y su uso. | |
| BR112015019524A2 (pt) | tratamento de combinação | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| CL2017001941A1 (es) | Uso de una mezcla de polímeros de glucosa modificadas para reducir metastasis de tumor | |
| CO7240357A2 (es) | Solución de acetaminofen supersaturada inyectable para la administración por la espina dorsal |